Cardiovascular risk in US adults with nonalcoholic steatohepatitis (NASH) vs. matched non-NASH controls, National Health and Nutrition Examination Survey, 2017–2020
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0309617 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Jonathan J Woolley und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medicus Economics, Boston, Massachusetts, United States of America. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Nutrition Surveys, Cardiovascular Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Madrigal Pharmaceuticals.
Abstract (Originalsprache)
Background
NASH is considered a contributor to atherosclerotic cardiovascular disease (ASCVD) risk; however, its contribution beyond traditional risk factors for CVD, particularly diabetes, is less clearly understood. This study aimed to quantify the cardiovascular-event risk associated with NASH, independent of diabetes status.
Methods
A cross-sectional analysis was conducted using the 2017–2020 NHANES pre-pandemic cycle. NASH was defined based on presence of steatosis without other causes of liver disease, and FibroScan+AST score from vibration-controlled transient elastography (VCTE). Significant fibrosis (stages F2-F4) was identified by liver stiffness measurement from VCTE. Predicted primary CV-event risk was estimated using both the Pooled Cohort Equations (PCE) and the Framingham Risk Score (FRS). NASH patients were matched with non-NASH controls on age, sex, race/ethnicity, and diabetes status. Weighted logistic regression was conducted, modeling elevated predicted CV risk (binary) as the dependent variable and indicators for NASH / fibrosis stages as independent variables.
Results
A sample of 125 NASH patients was matched with 2585 controls. NASH with significant fibrosis was associated with elevated predicted 10-year CV risk, although this association was only statistically significant in PCE analyses (odds ratio and 95% CI 2.34 [1.25, 4.36]). Analyses restricting to ages
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Medicus Economics, Boston, Massachusetts, United States of America.
- Formerly of Madrigal Pharmaceuticals, Conshohocken, Pennsylvania, United States of America.
- Pine Mountain Consulting, Redding, Connecticut, United States of America.
ORCID-Profile: Jonathan J Woolley
Förderung
- Madrigal Pharmaceuticals
Zitieren
APA
Woolley, J. J., Fishman, J., Parrinello, C. M., & O'Connell, T. (2024). Cardiovascular risk in US adults with nonalcoholic steatohepatitis (NASH) vs. matched non-NASH controls, National Health and Nutrition Examination Survey, 2017–2020. PLOS ONE. https://doi.org/10.1371/journal.pone.0309617
Vancouver
Woolley JJ, Fishman J, Parrinello CM, O'Connell T. Cardiovascular risk in US adults with nonalcoholic steatohepatitis (NASH) vs. matched non-NASH controls, National Health and Nutrition Examination Survey, 2017–2020. PLOS ONE. 2024. doi:10.1371/journal.pone.0309617
BibTeX
@article{Woolley2024,
author = {Woolley, Jonathan J and Fishman, Jesse and Parrinello, Christina M and O'Connell, Tom},
title = {Cardiovascular risk in US adults with nonalcoholic steatohepatitis (NASH) vs. matched non-NASH controls, National Health and Nutrition Examination Survey, 2017–2020},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0309617}
}
EUVIMED